# ProteinQure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proteinqure

- Industry: Biotechnology
- Headquarters: Toronto, Canada
- Website: www.proteinqure.com
- Total disclosed funding: $15M
- Latest round: Series A (May 27, 2025)
- Investors on record: 6

## About

ProteinQure Inc., based in Canada, specializes in developing advanced peptide-based drug delivery systems, leveraging innovative computational technology to enhance precision medicine for pharmaceutical applications.Founded in 2017 and headquartered in Toronto, Canada, ProteinQure Inc. focuses on peptide-based drug delivery systems. The company was founded by Christopher Ing, Lucas Siow, Mark Fingerhuth, and Tomas Babej, with Lucas Siow serving as CEO. ProteinQure has participated in 2 funding deals, with the most recent being a Series A round in May 2025, raising USD 11.00 mn from investors including Golden Ventures and Kensington Capital, bringing the total amount raised to USD 11.00 mn.ProteinQure specializes in the development of advanced peptide-based drug delivery systems aimed at transforming precision medicine. Their flagship offering, ProteinStudio™, is an integrated computational platform designed for innovative peptide design using sophisticated molecular simulations and custom AI models on petascale supercomputers. The proprietary peptides developed are engineered for targeted delivery, facilitating the intracellular transport of therapeutic payloads like cytotoxic agents, radioisotopes, and oligonucleotides. The company collaborates with Tier 1 pharmaceutical partners and operates in North America, Europe, and Asia, addressing the demand for targeted therapies that optimize efficacy while minimizing side effects.ProteinQure generates revenue through B2B partnerships, primarily with pharmaceutical companies seeking to improve their drug delivery systems. The company engages in structured agreements for the design and development of proprietary peptides, resulting in contract-based revenue streams. These contracts often involve milestone payments contingent on development phases and royalties from successful commercialization, with the ProteinStudio™ platform being integral to these arrangements.In May 2025, ProteinQure Inc. raised USD 11.00 mn in Series A funding, which will be utilized to support the clinical trial for PQ203. The company aims to expand its product offerings and enhance its market penetration in North America, Europe, and Asia. Specific targets for geographic expansion include regions with a high demand for targeted therapies, with plans to introduce new products based on their advanced peptide technology.

## Funding rounds

- Series A, May 27, 2025, $11M — Kensington Capital Partners, Golden Ventures
- Seed, Jul 25, 2019, $3.9M — Inovia Capital, Felicis Ventures, Golden Ventures, Global Founders Capital, 8VC

## Investors

- Inovia Capital (https://capitalatlas.ai/funds/inovia-capital) — Seed
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Seed
- Golden Ventures (https://capitalatlas.ai/funds/golden-ventures) — Seed, Series A
- Global Founders Capital (https://capitalatlas.ai/funds/global-founders-capital) — Seed
- 8VC (https://capitalatlas.ai/funds/8vc) — Seed
- Kensington Capital Partners — Series A